In fact, a recent study found that kids with ADHD sleep less at night and have poorer sleep quality than their peers without ADHD. These sleep issues impact their executive functi ...

Historically, clinical trials have under-represented women and minorities. Clinical Trial Media's Cara Brant offers ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

This research aims to evaluate how these specific interventions affect health outcomes. Phases of clinical trials — Phase 1 clinical trials. Phase 1 trials look at safety and dosage, and ...

NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today announced that it has engaged a Clinical Research Organization (CRO) to conduct a Phase II clinical trial advancing its broad ...

The Clinical Trials Market report delivers crucial insights into the ... this report acts as a strategic tool for organizations striving to meet their business goals. Phase I studies usually test new ...

accounted for 18% of the total sample size in the Phase 2 study. A consistent top-enroller in acute schizophrenia clinical trials, Segal Trials contributed to the study sample size with a rate of ...

with plans for Phase 2b clinical development in the U.S., and ongoing IND-enabling studies for PH80 targeting menopausal hot flashes. CFO Cindy Anderson reported research and development expenses ...

The abrupt termination of critical USAID-funded clinical trials, with insufficient time to safeguard the welfare of people who are participating, is profoundly unethical and utterly inexcusable.

We are excited to announce the initiation of our HORIZON Study for MZE829, a Phase 2 clinical trial with a novel, potential new medicine that could disrupt current treatment for AKD,” said Harold ...

CEO Brian Lian highlighted 2024 as an exceptionally busy year, with successful results from four studies, including the Phase 2 VENTURE trial for subcutaneous VK2735, which demonstrated up to 14.7% ...

Jan. 27, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (Company) (Nasdaq: ALLK), today announced topline results from its phase 1 clinical trial of AK006 in chronic spontaneous urticaria (CSU).